The Australian Pharmaceuticals Industries Ltd (ASX:API) share price will be on watch following the company’s release of a trading update.
The post Australian Pharmaceuticals (ASX:API) share price on watch after trading update appeared first on Motley Fool Australia. –
The Australian Pharmaceuticals Industries Ltd (ASX: API) share price will be on watch this morning following the company’s release of a trading update late Friday.
At the closing bell on Friday, which was prior to the announcement, the Australian Pharmaceuticals share price finished the day at $1.06, down 1.4%. A catalyst for the slight drop in the company’s shares could have been the broad sell-off in the market.
In comparison, the All Ordinaries Index (ASX: XAO) ended Friday’s session down 0.5% at 6,385 points.
Friday evening, Australian Pharmaceuticals provided shareholders with an update in relation to its full-year results, and the impacts of COVID-19.
For the period ending 31 August, the company advised its underlying net profit after tax (NPAT) will be broadly in line with market expectations. Australian Pharmaceuticals is expecting to report an underlying NPAT in the range of $30 million to $31 million.
The company noted that during the second-half, significant improvements in key balance sheet metrics were made. These included net debt and cash conversion days.
In addition, Australian Pharmaceuticals also made the decision to downsize its Priceline store network (non-pharmacy stores). Management said the closure of 14 Priceline stores, among other restructuring costs, are an outcome of the long-term impacts of COVID-19.
After reviewing its balance sheet to determine its core assets in the post-pandemic world, the company made several adjustments. The Soul Pattinson Chemist brand has been written down to the carrying value of $37.5 million. The pre-tax reduction is a one-off, non-cash item.
With the permanent closure of 14 non-pharmacy Priceline stores, Australian Pharmaceuticals completed a detailed stock review and identified surplus inventory. The company will seek to use these items in a clearance pricing strategy, further reducing working capital costs. This will create an NPAT reduction of $5.5 million, and will be considered as a non-cash accounting adjustment.
The company will announce its full-year results to the market on 22 October.
What did the CEO say?
Australian Pharmaceuticals Industries CEO, Richard Vincent, spoke about the Victorian COVID-19 restrictions, and the anticipated demand when lockdown laws ease. He said:
We currently have 14 Clear Skincare clinics and 22 Priceline company-owned stores temporarily closed in Victoria. These will re-open when COVID-19 lockdown rules allow. Where we have re-opened Clear Skincare clinics after mandated shutdowns, pent-up demand has been significant, with comparative sales up 25% on pre COVID-19 levels, followed by a sustained uplift. Since the half year, a further eight clinics have been opened, with the pipeline for further openings remaining strong.
Furthermore, Mr Vincent touched on Priceline’s performance. He added:
Priceline company stores and Priceline Pharmacies are also trading strongly compared to the same period last year in those States where COVID-19 restrictions have been lifted. Priceline’s online sales reflect growth of more than 100%, albeit from a low but growing base.
About the API share price
The API share price has been on a bumpy road over the last five years. The company reached a multi-year high in April 2017, but has been on a downhill trend ever since. With a market capitalisation of $522 million, the Australian Pharmaceuticals share price could be considered as modest with a price-to-earnings (P/E) ratio of 10.
Where to invest $1,000 right now
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.
*Returns as of June 30th
Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.